Half-life

2 h

Tmax

1 h

Category

peptide

Also known as: talpha1, zadaxin

Thymosin alpha-1 is a 28-amino-acid peptide with immunomodulatory properties, acting through toll-like receptor (TLR) signalling and T-cell maturation pathways. It is approved as Zadaxin in several countries for hepatitis B and C adjunct therapy. Its plasma half-life is approximately 2 hours. In the research setting, it has been investigated for immune enhancement, vaccine adjuvancy, and chronic infection support. Patients using thymosin alpha-1 should track dosing schedules, injection sites, and any immune-related effects.

Mechanism

A synthetic peptide identical to a naturally occurring thymic peptide. In research it is associated with immunomodulatory activity, including effects on T-cell function and innate immune signaling.

Research summary

Studied for immune-related applications; a branded product (thymalfasin/Zadaxin) is approved in some countries for certain conditions such as chronic hepatitis B and as an adjuvant, though it is not FDA-approved in the United States for general use. Evidence varies by indication.

Reported side effects

Reported effects are generally mild in studies, including injection-site reactions. The safety profile varies by population and indication, and comprehensive long-term data are limited outside approved uses.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

Thymosin alpha-1 (thymalfasin) immunomodulation review · peer-reviewed review article (2018)search PubMed for thymosin alpha 1 thymalfasin
Regulatory status note · FDA / international regulatory records (2020)approved in some countries; not FDA-approved in the US for general use; verify current status

References

Thymosin alpha-1 clinical reviewDOI: 10.1111/j.1749-6632.2010.05566.x

TrackPep slúži na vedenie záznamov. Zaznamenáva len to, čo zadáte, a nikdy neodporúča ani nevypočítava množstvá.